Literature DB >> 8729596

Patient perception of the diskus inhaler: a comparison with the turbuhaler inhaler.

M Schlaeppi1, K Edwards, R W Fuller, R Sharma.   

Abstract

Asthmatic patients who were regular and experienced users of the metered-dose inhaler (MDI) but with no history of powder inhaler use were interviewed by questionnaire. Most (71%) of the 159 adults recruited had suffered from asthma for more than five years; 89% had used an MDI for more than one year. In all, 153 (97%) found their current MDI easy or very easy to handle. Effectiveness in delivering the drug and ease of operation were the two features of the device they were most satisfied with. The two features 'of an ideal inhaler' rated most highly were the presence of a dose counter and ease of use during an attack (58% and 72% of respondents, respectively). Other important features included hygiene, sensation that a dose had been taken, and small size. When attitudes towards the Diskus inhaler and the Turbuhaler inhaler were compared, 108 (68%) would have been quite or very happy to have a Diskus inhaler prescribed for them, and 79 (50%) a Turbuhaler inhaler. The Diskus inhaler scored significantly better than the Turbuhaler inhaler for knowing how many doses were left, the presence of an attached cover, attractiveness (p < 0.001), hygiene, shape, weight (p = 0.001), and perceived ease of use (p = 0.002). The Turbuhaler inhaler scored significantly better in terms of size (p < 0.001). Overall, the Diskus inhaler was preferred by 104 of 159 patients (p < 0.001), with perceived ease of use, the dose counter, and shape cited as the main reasons for preference.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8729596

Source DB:  PubMed          Journal:  Br J Clin Pract        ISSN: 0007-0947


  11 in total

1.  Pectus excavatum: studiously ignored in the United Kingdom?

Authors:  R Wheeler; K Foote
Journal:  Arch Dis Child       Date:  2000-03       Impact factor: 3.791

2.  How to choose delivery devices for asthma.

Authors:  C O'Callaghan; P W Barry
Journal:  Arch Dis Child       Date:  2000-03       Impact factor: 3.791

Review 3.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

Review 4.  Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 5.  Once-daily inhaled corticosteroids in children with asthma: dry powder inhalers.

Authors:  C Möller
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 6.  Salmeterol/fluticasone propionate combination.

Authors:  C M Spencer; B Jarvis
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

7.  Comparing usability of NEXThaler(®) with other inhaled corticosteroid/long-acting β2-agonist fixed combination dry powder inhalers in asthma patients.

Authors:  Thomas Voshaar; Monica Spinola; Patrick Linnane; Alice Campanini; Daniel Lock; Anthony Lafratta; Mario Scuri; Barbara Ronca; Andrea S Melani
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-12-03       Impact factor: 2.849

8.  Does the inhalation device affect the bronchodilatory dose response curve of salbutamol in asthma and chronic obstructive pulmonary disease patients?

Authors:  Mariëlle E A C Broeders; Johan Molema; Wim C J Hop; Niek A Vermue; Hans T M Folgering
Journal:  Eur J Clin Pharmacol       Date:  2003-08-12       Impact factor: 2.953

Review 9.  Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.

Authors:  Katherine A Lyseng-Williamson; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 10.  The Diskus: a review of its position among dry powder inhaler devices.

Authors:  H Chrystyn
Journal:  Int J Clin Pract       Date:  2007-06       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.